Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142805 · ClinicalTrials.gov registry record · Phase 2
Tricaprilin in Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Cerecin.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00142805: Completed Phase 2 study, sponsored by Cerecin.
NCT00142805 is a Phase 2 study that has completed, run by Cerecin. The registered enrollment target is 152 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142805, a Phase 2 study, has completed, sponsored by Cerecin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.
Interventions
- OTHER Placebo
- DRUG Tricaprilin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2004-11-04 |
| Est. Completion | 2007-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142805
The ClinicalTrials.gov registry entry for NCT00142805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerecin, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00142805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142805 about?
NCT00142805 is a clinical study titled "Tricaprilin in Mild to Moderate Alzheimer's Disease". The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.
What is the current status of trial NCT00142805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2004-11-04. Estimated completion is 2007-01-07.
What interventions are being tested in trial NCT00142805?
The interventions under investigation include: Placebo (OTHER), Tricaprilin (DRUG).
Who is sponsoring clinical trial NCT00142805?
This trial is sponsored by Cerecin, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.